Five things for pharma marketers to know: Thursday, September 15, 2016

1. Mylan's CEO is scheduled to appear before the House Committee on Oversight and Government Reform to answer questions about price hikes associated with the EpiPen, its allergy shot. The company raised the price from $57 in 2007 to $600 for a two-pack in 2016. The panel is also expected to question a FDA official about the delay in approving a competing generic.  (Bloomberg)

2. Average employee health insurance premiums rose 3% in 2016, and the average deductible for these plans increased by 12%, a survey found. It also found that the Affordable Care Act did not drive up employer health insurance costs and instead employers switched employees from part-time to full-time work to make them eligible for health insurance. (CNBC)

3. GlaxoSmithKline's experimental shingles vaccine, Shingrix, showed 90% effectiveness in adults older than 70 years old for up to four years. The vaccine was more effective when treating older patients than Merck's Zostavax is. (Tech Times)

4. Intellectual property laws and economic incentives may be influencing worldwide access to drugs and devices, a new United Nations report found. The report noted that the industry's current model is “ill-equipped” to discover treatments for viruses such as Zika and Ebola, and it doesn't give millions of people access to drugs for treatable conditions. (Modern Healthcare)

5. A FDA advisory committee recommended that Pfizer would no longer be required to place a black-box warning on Chantix, its smoking-cessation drug. The warning was added to the label in 2008. (Stat)